Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
The DOI matches its Crossref record; 234 of the 235 references it cites were found in a registry or an index.
Abstract
The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is no solid evidence from liver imaging and/or histology in regards to a beneficial effect of metformin on MASLD components in clinical studies [168,169].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [168]
In the citing paper
“Peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), FXR and THR (particularly THR-β) are the most extensively studied receptors that are targets for therapy.20–22”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [22]
In the citing paper
“Activation of PPARs, particularly PPARβ/δ stimulation, promote the anti-inflammatory polarisation of hepatic macrophages,22,68”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [22]
In the citing paper
“Furthermore, controversially documented inter-species differences in PPAR-α expression [119][120][121] complicate the translation of data from preclinical studies to patients.[122,123]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [123]
Citations
Cites
1 retracted
Items 201–234 of 234
Bonds, D. E., Craven, T. E., Buse, J., Crouse, J. R., Cuddihy, R., Elam, M., Ginsberg, H. N., Kirchner, K., Marcovina, S., Mychaleckyj, J. C., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2524-2 · Cited by 64
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63
Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH)
Jindal, A., Bruzzì, S., Sutti, S., Locatelli, I., Bozzola, C., Paternostro, C., Parola, M., & Albano, E. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.06.015 · Cited by 62
Dynamic plasticity of macrophage functions in diseased liver
Ritz, T., Krenkel, O., & Tacke, F. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.007 · Cited by 58
Self-citationDeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 55
Rodriguez, M. A. D. L. R., Sugahara, G., Hooiveld, G. J. E. J., Ishida, Y., Tateno, C., & Kersten, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4834-3 · Cited by 54
The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
Devchand, P. R., Liu, T., Altman, R. B., FitzGerald, G. A., & Schadt, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01093 · Cited by 54
Young, L. H., Viscoli, C. M., Schwartz, G. G., Inzucchi, S. E., Curtis, J. P., Gorman, M. J., Furie, K. L., Conwit, R., Spatz, E. S., Lovejoy, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034763 · Cited by 52
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2985 · Cited by 49
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.024 · Cited by 49
Cariou, B., Hanf, Lambert-Porcheron, S., & Zair (2013) · Diabetes Care · Cited by 49
Dietz, M., Mohr, P., Kuhn, B., Maerki, H. P., Hartman, P., Ruf, A., Benz, J., Grether, U., & Wright, M. B. (2012) · ChemMedChem · doi:10.1002/cmdc.201100598 · Cited by 47
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 47
Portillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12833 · Cited by 43
Self-citationZhao, N., Mi, L., Zhang, X., Xu, M., Yu, H., Liu, Z., Liu, X., Guan, G., Gao, W. D., & Wang, J. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.03.006 · Cited by 38
Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?
Grunhut, J., Wang, W., Aykut, B., Gakhal, I., Torres-Hernandez, A., & Miller, G. (2018) · EMJ Hepatology · doi:10.33590/emjhepatol/10312252 · Cited by 38
A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Targher, G., & Byrne, C. D. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.1502 · Cited by 33
Self-citationWang, Z., Tao, Y., Qiu, T., Yao, X., Jiang, L., Wang, N., Wei, S., Jia, X., Pei, P., Yang, G., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.01.019 · Cited by 33
Kim, S. M., Lee, B., An, H. J., Kim, D. H., Park, K. C., Noh, S., Chung, K. W., Lee, E. K., Kim, K. M., Kim, D. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17695 · Cited by 24
Ham, S. A., Hwang, J. S., Yoo, T., Lee, W. J., Paek, K. S., Oh, J., Park, C., Kim, J., Tae, J., Kim, J.-H., et al. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.10.005 · Cited by 23
Adiponectin regulates AQP3 via PPARα in human hepatic stellate cells
Tardelli, M., Claudel, T., Bruschi, F. V., Moreno‐Viedma, V., & Trauner, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.009 · Cited by 23
Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease
Fleet, S. E., Lefkowitch, J. H., & Lavine, J. E. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.01.002 · Cited by 22
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?
Pap, A., Cuaranta‐Monroy, I., Peloquin, M., & Nagy, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081236 · Cited by 21
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
Munigoti, S. P., & Harinarayan, C. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131134 · Cited by 21
Francque, S., Maeght, S. D., Adler, M., Deltenre, P., de Galocsy, C., Orlent, H., Steenbergen, W. V., Bastens, B., Wain, E., Langlet, P., et al. (2011) · PubMed · Cited by 19
Self-citationPark, J. R., Ahn, J. H., Jung, M. H., Koh, J., Park, Y., Hwang, S., Jeong, Y., Kwak, C. H., Lee, Y. S., Seo, H. G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148510 · Cited by 16
Identification of fibronectin binding sites in dermatopontin and their biological function
Kato, A., Okamoto, O., Wu, W., Matsuo, N., Kumai, J., Yamada, Y., Katagiri, F., Nomizu, M., & Fujiwara, S. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.07.003 · Cited by 13
Hoogwerf, B. J., Manner, D. H., Fu, H., Moscarelli, E., Gaydos, B. L., & Heine, R. J. (2016) · Diabetes Care · doi:10.2337/dcs15-3025 · Cited by 10
Peymani, M., Ghaedi, K., Irani, S., & Nasr‐Esfahani, M. H. (2016) · PubMed Central · doi:10.22074/cellj.2016.4317 · Cited by 7
Hirschfield, G. M., Boudes, P. F., Bowlus, C. L., Gitlin, N., Michael, G., Harrison, S. A., Gordon, S. C., Aspinall, R., Döerffel, Y., Kremer, A. E., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30429-x · Cited by 5
The problem-oriented health record.
Calhoun, N. R. (1973) · PubMed · Cited by 3
[Malignant endocarditis lenta or Osler's disease].
Jj, M. (1969) · PubMed · Cited by 2
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Research works printed but not linked: 3
- CymaBay Therapeutics. CymaBay Therapeutics reports topline 12-week data from an ongoing phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=2 (2019).
- CymaBay Therapeutics. CymaBay Therapeutics halts clinical development of seladelpar. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=1 (2019).
- Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 42, 1481–1488 (2019). · DOI · Paper page
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationA Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citation
Metadata
- Authors
- Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F.
- Affiliations
- University of Antwerp (BE)
- Duke University (US)
- University Hospital Southampton NHS Foundation Trust (GB)
- University of Florida Health (US)
- University Hospital of Bern (CH)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Brigham and Women's Hospital (US)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Francque, Sven
- ORCID
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-10-22
- Volume
- 18
- Issue
- 1
- Pages
- 24-39
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3094033262
- Cited by
- 316
- References
- 235
- Citations by year
- 2026: 38 · 2025: 41 · 2024: 62 · 2023: 62 · 2022: 70 · 2021: 41 · 2020: 2
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, peroxisome proliferator-activated receptors, non-alcoholic fatty liver disease, metabolic syndrome, obesity, type 2 diabetes, liver fibrosis, PPAR agonists, gut microbiota
- MeSH terms
- Humans, Inflammation, Obesity, Disease Progression, Metabolic Syndrome, Peroxisome Proliferator-Activated Receptors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.